Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Systemic gene delivery of RO7494222 (SRP-9001) in children under four with Duchenne muscular dystrophy
2022-000691-19Phase 2Active
- Sponsor
- Roche
- Start
- Jul 2022
- Modality
- Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of delandistrogene moxeparvovec in Duchenne muscular dystrophy (DMD), sponsored by Roche. Primary endpoint: Incidence of treatment-emergent adverse events. Started Jul 2022; status: active.
02
Drugs
delandistrogene moxeparvovec
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on 2022-000691-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000691-19.